Kevin Cheng

Kevin Cheng is a Partner at MVM Partners LLP, where expertise lies in investing in growth-stage companies within the healthcare sector, including medical technology and digital health. Cheng serves as a Board Member for BioProtect Ltd and OSSIO, and held the position of Board Observer for Paragon 28, which is listed on the NYSE. Previous board roles include Zipline Medical, acquired by Stryker in 2019, and Cheetah Medical, acquired by Baxter in 2019. Prior to MVM Partners LLP, Cheng worked as a Consultant at Bain & Company and researched at the Medical Research Council, focusing on neural development and cell reprogramming. Academic credentials include a PhD in Oncology and a BA in Natural Sciences from the University of Cambridge, where Cheng also contributed as a College Supervisor in biochemistry and molecular biology.